p27kip1 contributions to cancer.
Deregulation of the tumor suppressor p27kip1 (p27) has been implicated in a variety of human cancers, suggesting it might be a viable therapeutic target. Developing p27-specific intervention strategies requires understanding its role and regulation in normal and pathologic states. Although p27 has been extensively characterized as an inhibitor of cyclin-dependent kinases, disruption of this function is inadequate to explain its role in tumorigenesis. A more comprehensive understanding of p27 biology would facilitate development of therapeutic responses to p27 disruption in human cancers.
Cancer Center, MMC 806, 420 Delaware St. SE, University of Minnesota, Minneapolis, MN 55455, USA.
Richard Seonghun
RS
Nho
Robert J
RJ
Sheaff
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology*; D018797:Cell Cycle Proteins / Q000187:drug effects / Q000235:genetics; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D016213:Cyclins / Q000378:metabolism; D004195:Disease Models, Animal; D025461:Feedback, Physiological / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000172:deficiency* / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D018797:Cell Cycle Proteins; D016213:Cyclins; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases